abacavir / lamivudine
Kivexa is used with at least one other antiviral medicine to treat adults and children weighing at least 25 kg who are infected with human immunodeficiency virus (HIV), the virus that causes acquired immune deficiency syndrome (AIDS).
Kivexa contains two active substances, abacavir and lamivudine.
Kivexa : EPAR - Medicine overview (PDF/129.24 KB)
First published: 14/01/2008
Last updated: 23/07/2020
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
ViiV Healthcare BV
|Date of issue of marketing authorisation valid throughout the European Union||
Van Asch van Wijckstraat 55H
20/08/2021 Kivexa - EMEA/H/C/000581 - WS1990
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Antivirals for treatment of HIV infections, combinations
Antivirals for systemic use
Kivexa is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults, adolescents and children weighing at least 25 kg.
Before initiating treatment with abacavir, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patients known to carry the HLA-B*5701 allele.